Using the industry peer median EV/Revenue multiple (trailing + forward), Tilray Brands, Inc. (TLRY) has a fair value of $47.43 based on 8 comparable companies in the Drug Manufacturers - Specialty & Generic industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Tilray Brands, Inc.TLRY | 504 | 0.6x | 0.8x |
| Immunome, Inc. | 1,972 | 190.5x | — |
| Neogen Corporation | 1,970 | 3.1x | 3.2x |
| Intellia Therapeutics, Inc. | 1,665 | 23.7x | 26.9x |
| Phibro Animal Health Corporation | 1,622 | 1.8x | 2.3x |
| Maze Therapeutics, Inc. | 1,438 | 7.6x | 101.4x |
| Harrow Health, Inc. | 1,425 | 5.9x | 4.6x |
| Alvotech | 1,017 | 3.9x | 3.7x |
| Amphastar Pharmaceuticals, Inc. | 846 | 1.9x | 1.8x |
| Industry Median | 4.9x | 3.7x | |
| (*) Revenue | 1,127 | 864 | |
| = Enterprise Value | 5,524 | 3,216 | |
| (-) Net Debt | 147 | 147 | |
| Equity Value | 5,377 | 3,069 | |
| (/) Outstanding shares | 89 | 89 | |
| Fair Price | $60 | $34 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.